Home > Author

Blog Posts by Author: XIFIN

The First Steps in Preparing for the PAMA Reporting Period (Part 1)

Solid reporting from all applicable laboratories is the key to mitigate future PAMA fee schedule cuts. This means labs need to be able to report on actual allowables vs. payments, validate the accuracy of payments, and optimize appeals activity to avoid under-reporting payments. All applicable labs are included in the current data collection period now underway for the first half of 2019.Step 1:...


EKRA‘s Real Impact on Clinical Laboratories

With the opioid epidemic becoming an increasingly serious issue in the United States, our government has responded with the Substance Use-Disorder Prevention that Promotes Opioid Recover and Treatment for Patients and Communities Act, also known as the Support Act. This act essentially aimed to reduce access to opioids. One of more than 70 bills in the Support Act is the Eliminating...


Can Your Revenue Cycle Management (RCM) Solution Keep Up with Your Future Plans?

Shrinking reimbursements and increasingly complex regulations are squeezing the profits of clinical laboratories. As a result, many clinical laboratory leaders are being forced to consider their strategic options, including reorganizing, restructuring, merging and or otherwise consolidating with another laboratory, or selling. This means laboratory leaders need to be closely assessing their...


What You Need to Know About the Changing Landscape and the Impact to How Labs Must Submit Claims to Enable Reimbursements

Prior authorization in the medical field is a necessary but flawed process that causes challenges for physicians as well as everyone involved from submission to approval. For those who are unaware, prior authorization is a requirement that a physician obtains approval from a patients health insurance plan to prescribe a specific medication or lab test. Prior authorization is a technique...


How to Prepare Your Lab for Next-Gen Sequencing and Big Data Science

Industry experts estimate that anywhere between 100 million to 2 billion genomes will be sequenced by 2025. With the growing demand for next-generation sequencing (NGS), from bases to whole genomes, and the growing demand for sequence-based drug discovery applications and diagnostic testing, there’s no denying that labs will need to accommodate a huge amount of data very soon.What does genomics...